[go: up one dir, main page]

SG11202100374XA - Therapeutic dendrimer - Google Patents

Therapeutic dendrimer

Info

Publication number
SG11202100374XA
SG11202100374XA SG11202100374XA SG11202100374XA SG11202100374XA SG 11202100374X A SG11202100374X A SG 11202100374XA SG 11202100374X A SG11202100374X A SG 11202100374XA SG 11202100374X A SG11202100374X A SG 11202100374XA SG 11202100374X A SG11202100374X A SG 11202100374XA
Authority
SG
Singapore
Prior art keywords
dendrimer
therapeutic
therapeutic dendrimer
Prior art date
Application number
SG11202100374XA
Inventor
David James Owen
Brian Devlin Kelly
Original Assignee
Starpharma Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018902611A external-priority patent/AU2018902611A0/en
Application filed by Starpharma Pty Ltd filed Critical Starpharma Pty Ltd
Publication of SG11202100374XA publication Critical patent/SG11202100374XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers
    • C08G83/004After treatment of dendrimers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10Alpha-amino-carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Epoxy Compounds (AREA)
  • Peptides Or Proteins (AREA)
SG11202100374XA 2018-07-19 2019-07-19 Therapeutic dendrimer SG11202100374XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018902611A AU2018902611A0 (en) 2018-07-19 Therapeutic dendrimer
PCT/AU2019/050759 WO2020014750A1 (en) 2018-07-19 2019-07-19 Therapeutic dendrimer

Publications (1)

Publication Number Publication Date
SG11202100374XA true SG11202100374XA (en) 2021-02-25

Family

ID=69163458

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202100374XA SG11202100374XA (en) 2018-07-19 2019-07-19 Therapeutic dendrimer

Country Status (12)

Country Link
US (2) US11118016B2 (en)
EP (1) EP3823961A4 (en)
JP (1) JP7588065B2 (en)
KR (1) KR102811484B1 (en)
CN (1) CN112424178B (en)
AU (1) AU2019306745B2 (en)
BR (1) BR112021000658A2 (en)
CA (1) CA3106568A1 (en)
MX (1) MX2021000677A (en)
SA (1) SA521421036B1 (en)
SG (1) SG11202100374XA (en)
WO (1) WO2020014750A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12071517B2 (en) 2018-07-19 2024-08-27 Starpharma Pty Ltd. Therapeutic dendrimer
AU2019306745B2 (en) 2018-07-19 2024-08-08 Starpharma Pty Ltd Therapeutic dendrimer
US20230263900A1 (en) * 2020-08-31 2023-08-24 Starpharma Pty Ltd. Dendrimer-drug conjugate
KR20230079035A (en) * 2020-09-14 2023-06-05 주하이 베이하이 바이오테크 컴퍼니 리미티드 Formulations of Cabazitaxel
EP4431116A4 (en) * 2021-11-08 2025-01-15 Shanghai Best-Link Bioscience, LLC DRUG CONJUGATE BASED ON EPSILON-POLY-L-LYSINE, INTERMEDIATE THEREOF, AND ITS APPLICATION

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840900A (en) 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US6230913B1 (en) 1998-01-30 2001-05-15 The Popstraw Company, Llc Straw in a bottle
KR100729015B1 (en) 2000-01-04 2007-06-14 어섹스 팔마큐티칼스 인코포레이티드 N, O-amidomalonate platinum complex
US6471968B1 (en) * 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
DE10041559A1 (en) 2000-08-24 2002-03-07 Basf Ag Use of copolymer of amino acid and co-condensable compound in cosmetic and dermatological products, has better water solubility than polyamino acids
AUPR412801A0 (en) * 2001-03-30 2001-05-03 Starpharma Limited Agent for the prevention and treatment of sexually transmitted disease s - I
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US20100136614A1 (en) 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
HUE031341T2 (en) 2005-10-25 2017-07-28 Starpharma Pty Ltd Macromolecular compounds having controlled stoichiometry
WO2007080114A2 (en) * 2006-01-11 2007-07-19 Biotech Igg Ab Macromolecule conjugate
WO2007082331A1 (en) * 2006-01-20 2007-07-26 Starpharma Pty Limited Modified macromolecule
WO2008017122A1 (en) 2006-08-11 2008-02-14 Starpharma Pty Ltd Polylysine dendrimer contrast agent
PL2052011T3 (en) 2006-08-11 2021-03-08 Starpharma Pty Limited Targeted polylysine dendrimer therapeutic agent
DK2306986T3 (en) 2008-06-26 2018-06-18 Prolynx Llc PRODRUGS AND PHARMACEUTICAL Macromolecule Conjugates with Controlled Drug Release Rates
JP2012522055A (en) * 2009-03-30 2012-09-20 セルリアン・ファーマ・インコーポレイテッド Polymer-drug conjugates, particles, compositions, and related methods of use
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates
EP2571496A4 (en) 2010-05-05 2016-03-30 Prolynx Llc Controlled drug release from dendrimers
DK2566335T3 (en) 2010-05-05 2016-10-03 Prolynx Llc Controlled release of active ingredients from macromolecular CONJUGATES
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
FR2967581B1 (en) * 2010-11-19 2012-12-28 Sanofi Aventis POLYMERIC CONJUGATES OF ACTIVE INGREDIENTS, PROCESS FOR THEIR PREPARATION AND POLYMERIC INTERMEDIATES
CN102120036B (en) 2011-02-22 2013-07-24 中国科学院长春应用化学研究所 Nano micelle of biodegradable macromolecular-bonding Pt(IV) anti-cancer medicament and preparation method thereof
PT2729179T (en) * 2011-06-06 2020-11-25 Starpharma Pty Ltd Macromolecules
US20180326081A1 (en) 2011-06-06 2018-11-15 Starpharma Pty Ltd Macromolecules
CA2843875C (en) * 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CA2882958A1 (en) 2012-08-29 2014-03-06 Mannkind Corporation Method and composition for treating hyperglycemia
WO2015035446A1 (en) * 2013-09-10 2015-03-19 Starpharma Pty Ltd Macromolecules of dendrimer-platinum conjugates
WO2015184510A1 (en) * 2014-06-06 2015-12-10 Starpharma Pty Ltd Dendrimer-drug conjugates
US11369688B2 (en) * 2016-09-15 2022-06-28 The Regents Of The University Of California Hybrid telodendrimers
AU2019306745B2 (en) 2018-07-19 2024-08-08 Starpharma Pty Ltd Therapeutic dendrimer

Also Published As

Publication number Publication date
KR20210034011A (en) 2021-03-29
CN112424178B (en) 2025-01-28
US11118016B2 (en) 2021-09-14
US11970583B2 (en) 2024-04-30
MX2021000677A (en) 2021-03-25
EP3823961A1 (en) 2021-05-26
US20210380765A1 (en) 2021-12-09
SA521421036B1 (en) 2024-02-26
AU2019306745A1 (en) 2021-02-18
EP3823961A4 (en) 2022-06-08
WO2020014750A1 (en) 2020-01-23
CA3106568A1 (en) 2020-01-23
BR112021000658A2 (en) 2021-04-13
AU2019306745B2 (en) 2024-08-08
CN112424178A (en) 2021-02-26
KR102811484B1 (en) 2025-05-22
JP7588065B2 (en) 2024-11-21
US20200392295A1 (en) 2020-12-17
JP2021529818A (en) 2021-11-04

Similar Documents

Publication Publication Date Title
SG11202104461XA (en) Therapeutic methods
IL277336A (en) Combination therapy
IL268648B (en) Therapeutic dendrimers
GB201804255D0 (en) Macrophage-based therapy
IL283327A (en) Therapeutic dendrimer
SG11202100374XA (en) Therapeutic dendrimer
GB201716942D0 (en) Therapeutic compounds
GB201819853D0 (en) Therapy
IL280729A (en) Combination therapy
IL279908A (en) Combination therapy
SG11202101518QA (en) Combination therapy
GB201817385D0 (en) Therapy
HK40108454A (en) Therapeutic dendrimers
HK40050340A (en) Therapeutic dendrimer
HK40048868A (en) Therapeutic dendrimer
AU2018904431A0 (en) Therapeutic Dendrimer
AU2018902611A0 (en) Therapeutic dendrimer
GB201807147D0 (en) Therapeutic combination
GB201819936D0 (en) Therapeutic methods
GB201820895D0 (en) Therapy
GB201815579D0 (en) Combination therapy
GB201814207D0 (en) Combination Therapy
GB201814038D0 (en) Ilven therapy
GB201805660D0 (en) Combination Therapy
GB201805189D0 (en) Combination therapy